MARKET

XBIO

XBIO

Xenetic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.210
+0.040
+1.26%
After Hours: 3.190 -0.02 -0.62% 17:05 07/28 EDT
OPEN
2.930
PREV CLOSE
3.170
HIGH
3.530
LOW
2.930
VOLUME
6.40M
TURNOVER
--
52 WEEK HIGH
5.85
52 WEEK LOW
0.7600
MARKET CAP
28.08M
P/E (TTM)
-1.9061
1D
5D
1M
3M
1Y
5Y
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-sp...
ACCESSWIRE · 3h ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investor Place · 9h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Acutus Medical (NASDAQ:AFIB) stock increased by 9.61% to $16.3 during Tuesday's after-market session. The market value of their outstanding shares is at $548.0 million.
Benzinga · 1d ago
Xenetic Biosciences (NASDAQ:XBIO) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 1d ago
34 Stocks Moving in Tuesday's Pre-Market Session
Gainers Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares rose 139.7% to $7.48 in pre-market trading after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for roughly $7.1 million.
Benzinga · 1d ago
74 Biggest Movers From Yesterday
Gainers
Benzinga · 1d ago
XBIO Stock: Xenetic Soars on Private Placement Announcement
Investor Place · 2d ago
BEKE, SGRP, FHS among mid-day movers
Gainers: Tyme Technologies TYME +64%.Bit Digital BTBT +49%.SPAR Group (SGRP) +41%.Xenetic Biosciences XBIO +26%.IMV IMV +25%.Studio City International Holdings MSC +25%.Bitfarms BITF +24%.MicroStrategy MSTR +22%.Riot Blockchain RIOT +21%.RBC Bearings ROLL ...
Seekingalpha · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XBIO. Analyze the recent business situations of Xenetic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XBIO stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 558.16K
% Owned: 6.38%
Shares Outstanding: 8.75M
TypeInstitutionsShares
Increased
6
169.66K
New
3
117.97K
Decreased
0
0
Sold Out
1
32.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.64%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Chief Executive Officer/Chief Operating Officer/Director
Jeffrey Eisenberg
Chief Financial Officer/Chief Accounting Officer
James Parslow
Chief Scientific Officer
Curtis Lockshin
Treasurer/Secretary/Director
Colin Hill
Director
Grigory Borisenko
Director
Timothy Cote
Director
Firdaus Dastoor
Director
Artur Isaev
Director
Roger Kornberg
Independent Director
James Callaway
Independent Director
Adam Logal
No Data
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The Company is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.

Webull offers kinds of Xenetic Biosciences Inc stock information, including NASDAQ:XBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIO stock methods without spending real money on the virtual paper trading platform.